Annovis Bio (ANVS) Long-Term Debt Issuances (2019)
Annovis Bio (ANVS) posted Long-Term Debt Issuances of $530000.0 for Q1 2019.
Annovis Bio (ANVS) Long-Term Debt Issuances (2019) Analysis & Trends
Annovis Bio has reported Long-Term Debt Issuances for 1 years, with the latest figure at $530000.0 in Q1 2019.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $530000.0 in Q1 2019, while the trailing twelve-month figure through Dec 2019 was $530000.0 (changed N/A YoY) and the FY2019 annual result came in at $530000.0, changed N/A from the prior year.
- Long-Term Debt Issuances was little changed at $530000.0 in Q1 2019 per ANVS's latest filing.
- Over five years, Long-Term Debt Issuances peaked at $530000.0 in Q1 2019 and troughed at $530000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 530,000.00 |
| Mar 31, 2019 | 530,000.00 |